There is limited research on how a large-scale pandemic affects different aspects of OCD. Here, read about 2 cases in which there was significant deterioration in symptoms of OCD in the context of the COVID-19 pandemic.
This study examined the use of injectable paliperidone palmitate in Black/African American patients with schizophrenia and prior criminal justice system involvement. Read it to see if treatment failures were reduced with paliperidone vs oral medications.
Incidents involving both a homicide and a suicide are rare and vary widely in terms of motive and circumstances. Read this study to learn about 8 classifications of homicide-suicides the authors developed using a large database.
This report describes the successful treatment of 4 adult men who presented with concerns about problematic sexual interests and behaviors that began after treatment with pramipexole related to Parkinson’s disease or restless leg syndrome.
About 10% of patients diagnosed with OCD remain symptomatic despite standard pharmaceutical and psychotherapy treatments. This brief report discusses the possible role of transcranial magnetic stimulation in the treatment of these patients.
Women seem more likely than men to develop obsessive-compulsive disorder (OCD), but findings of individual studies are inconsistent. This meta-analysis estimated the worldwide prevalence of OCD to determine if the disorder is indeed more common in women.
This case series includes 3 patients diagnosed with papillary thyroid carcinoma who also had subthreshold obsessive-compulsive symptoms. Read on to find out about the diagnostic process and course of treatment.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”